Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) is a late-onset neurodegenerative condition caused by a premutation expansion (55-200 CGG repeats) in the FMR1 gene located at chromosome Xq27.3[1]. Unlike full-mutation Fragile X syndrome, which results from FMR1 silencing and FMRP deficiency, FXTAS results from a toxic gain-of-function mechanism centered on the expanded CGG repeat RNA[2].
The disease primarily affects males, with symptoms emerging in the sixth decade: progressive cerebellar ataxia, intention tremor, peripheral neuropathy, and cognitive decline. Approximately 50% of affected individuals develop dementia[1:1].
The FMR1 premutation allele (55-200 CGG repeats) is transcriptionally distinct from both normal alleles (<45 repeats) and full-mutation alleles (>200 repeats)[3]:
The expanded CGG repeat tract causes transcriptional dysregulation through multiple mechanisms[3:1]:
The expanded CGG repeat RNA folds into stable secondary structures including hairpins and G-quadruplexes[2:1]. These structures are the primary mediators of RNA toxicity in FXTAS:
The CGG repeat RNA accumulates in nuclear foci that sequester essential RNA-binding proteins[1:2][4]:
Key sequestered proteins:
| Protein | Normal Function | Sequestration Effect |
|---|---|---|
| Pur-alpha | mRNA transport, dendritic targeting | Deficit in synaptic translation[4:1] |
| hnRNP A2/B1 | mRNA splicing, stability | Altered RNA processing |
| SAM68 | Signal transduction, RNA metabolism | Disrupted neuronal signaling |
| Ddx5/Ddx17 | DEAD-box helicases | Impaired RNA unwinding |
The sequestration of Pur-alpha is particularly critical for neuronal function[4:2]:
RAN translation is a non-canonical form of protein synthesis that occurs bidirectionally from expanded repeat sequences in the absence of a start codon[5][6]. The CGG repeat is translated in all three reading frames:
The primary toxic product of CGG RAN translation is FMRpolyG (polyglycine-containing protein)[5:1]:
Characteristics of FMRpolyG:
FMRpolyG accumulation drives neurodegeneration through multiple pathways[8][9]:
FMRpolyG physically interacts with mitochondrial proteins, particularly subunits of Complex I[8:1][10]:
The resulting mitochondrial dysfunction generates elevated levels of reactive oxygen species[10:1]:
Cerebellar Purkinje cells and other affected neurons experience:
FXTAS involves significant neuroinflammatory components[11][12]:
Astrocytes are affected in FXTAS through:
The neuroinflammation in FXTAS shares features with other repeat expansion disorders:
MRI reveals characteristic white matter changes in FXTAS[1:3]:
White matter vulnerability in FXTAS results from:
FXTAS shares overlapping features with frontotemporal dementia and Parkinson's disease, but has distinct mechanisms:
| Feature | FXTAS | FTD | PD |
|---|---|---|---|
| Tremor | Intention tremor | Usually absent | Resting tremor |
| Ataxia | Prominent cerebellar | Less common | Can occur |
| Cognitive | Executive dysfunction | Behavioral//language | Dementia later |
| Pathology | FMRpolyG inclusions | Tau/TDP-43 | Alpha-synuclein |
| MRI | MCP sign, cerebellar atrophy | Frontal-temporal atrophy | Midbrain atrophy |
RNA-targeted approaches:
RAN translation inhibition:
Mitochondrial protectants:
Protein clearance:
Neuroinflammation modulation:
Current clinical trials for FXTAS focus on:
Hagerman, R. J., & Hagerman, P. Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management. Nature Reviews Neurology. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Malik, I., Kelley, C. P., Wang, E. T., & Todd, P. K. Molecular mechanisms underlying nucleotide repeat expansion disorders. Nature Reviews Molecular Cell Biology. 2021. ↩︎ ↩︎
Kenneson, A., et al. FMR1 transcriptional dynamics across CGG repeat sizes. Human Molecular Genetics. 2005. ↩︎ ↩︎
Brown, S. S., et al. Pur-alpha functionally compensates for TLS in FXTAS pathogenesis. Acta Neuropathologica. 2018. ↩︎ ↩︎ ↩︎
Todd, P. K., Oh, S. Y., Krans, A., et al. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron. 2013. ↩︎ ↩︎
Krans, A., et al. Repeat-associated non-AUG translation in FXTAS and ALS. Neuron. 2016. ↩︎
Greco, C. M., et al. Neuronal intranuclear inclusions in a large FXTAS cohort. Acta Neuropathologica. 2012. ↩︎ ↩︎
Krishnan, A., et al. FMRpolyG interacts with mitochondrial proteins and impairs complex I function. Cellular and Molecular Life Sciences. 2022. ↩︎ ↩︎
Yang, M., et al. FMRpolyG toxicity in human neurons and astrocytes. Neurobiology of Disease. 2017. ↩︎
Johri, A., & Beal, M. F. Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics. 2012. ↩︎ ↩︎
Bujing, A., & Hagerman, R. J. Neuroinflammation and oxidative stress in FMR1 premutation carriers. Journal of Neuroimmunology. 2014. ↩︎
Auzmendi, J., et al. FMR1 premutation: from neuroinflammation to neurodegeneration. Neural Regeneration Research. 2022. ↩︎
卖了, M., Tran, T., Li, Y., et al. Targeting FMR1 premutation RNAs with antisense oligonucleotides in a mouse model of fragile X-associated tremor/ataxia syndrome. Brain. 2020. ↩︎